Thursday's Small-Cap Winners & Losers
Small stocks underperformed the broader market for the second straight session Thursday even as several companies rode high on various good news.
One of the day's best performers was Dusa Pharmaceuticals (DUSA), lately rocketing 57% in extremely heavy trading after the Food and Drug Administration granted "orphan drug" status to Levulan, the Wilmington, Mass., biotech's proposed therapy for esophageal dysplasia. The disease sometimes occurs in patients with Barrett's esophagus and is a high-risk possible precursor to esophageal cancer.
Orphan drug designation, given to promising drugs for treatment of rare diseases, allows for seven years of marketing exclusivity on FDA approval as well as possible grants and tax incentives during the developmental stage. Dusa shares surged $1.58 to $4.35.
Nextar Broadcasting (NXST) also came out on top amid news it's considering selling itself, having retained Goldman Sachs to review this and other strategic alternatives. The Irving, Texas, TV broadcaster surged 20.1% to $13.08.Massachusetts-based TechTarget (TTGT), which operates a network of information-technology-products Web sites, jumped 16% to $15.08 following its 7.7-million-share initial public offering. A couple of small names meanwhile fired up on positive analyst calls. Information-technology company Stanley (SXE) leapt 9.7% to $17.71 after Wachovia upped it to outperform on the heels of impressive fiscal fourth-quarter results, and Lehman Brothers began coverage on Input/Output (IO) with an overweight rating. The company, which sells seismic products and services to the oil-and-gas industry, recently added 3.4% to $14.23.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV